Connect with us

Health

New Jersey woman recovering after receiving successful pig kidney transplant

Published

on

New Jersey woman recovering after receiving successful pig kidney transplant
  • Lisa Pisano faced heart and kidney failure, rendering her ineligible for traditional transplants, but a pioneering procedure at NYU Langone Health offered hope.
  • Doctors implanted a mechanical heart pump to stabilize Pisano’s failing heart, followed by a kidney transplant from a genetically modified pig.
  • Pisano’s recovery is progressing well, marking a significant advancement in animal-to-human transplantation.

Doctors have transplanted a pig kidney into a New Jersey woman who was near death, part of a dramatic pair of surgeries that also stabilized her failing heart.

Lisa Pisano’s combination of heart and kidney failure left her too sick to qualify for a traditional transplant, and out of options. Then doctors at NYU Langone Health devised a novel one-two punch: Implant a mechanical pump to keep her heart beating and days later transplant a kidney from a genetically modified pig.

Pisano is recovering well, the NYU team announced Wednesday. She’s only the second patient ever to receive a pig kidney — following a landmark transplant last month at Massachusetts General Hospital – and the latest in a string of attempts to make animal-to-human transplantation a reality.

MASSACHUSETTS MAN, RECIPIENT OF FIRST SUCCESSFUL PIG KIDNEY TRANSPLANT, IS DISCHARGED FROM HOSPITAL

This week, the 54-year-old grasped a walker and took her first few steps.

Lisa Pisano looks at photos of her dog after her surgeries at NYU Langone Health in New York on April 22, 2024. Doctors transplanted a pig kidney into Pisano, who was near death, part of a dramatic pair of surgeries that also included a fix for her failing heart. (AP Photo/Shelby Lum)

Advertisement

“I was at the end of my rope,” Pisano told The Associated Press. “I just took a chance. And you know, worst case scenario, if it didn’t work for me, it might have worked for someone else and it could have helped the next person.”

Dr. Robert Montgomery, director of NYU Langone Transplant Institute, recounted cheers in the operating room as the organ immediately started making urine.

“It’s been transformative,” Montgomery said of the experiment’s early results.

But “we’re not off the hook yet,” cautioned Dr. Nader Moazami, the NYU cardiac surgeon who implanted the heart pump.

“With this surgery I get to see my wife smile again,” Pisano’s husband Todd said Wednesday.

Advertisement

FEDS INVESTIGATE TEXAS SURGEON ACCUSED OF DENYING PATIENTS LIFE-SAVING LIVER TRANSPLANTS

Other transplant experts are closely watching how the patient fares.

“I have to congratulate them,” said Dr. Tatsuo Kawai of Mass General, who noted that his own pig kidney patient was healthier overall going into his operation than NYU’s patient. “When the heart function is bad, it’s really difficult to do a kidney transplant.”

THE PIG ORGAN QUEST

More than 100,000 people are on the U.S. transplant waiting list, most who need a kidney, and thousands die waiting. In hopes of filling the shortage of donated organs, several biotech companies are genetically modifying pigs so their organs are more humanlike, less likely to be destroyed by people’s immune system.

NYU and other research teams have temporarily transplanted pig kidneys and hearts into brain-dead bodies, with promising results. Then the University of Maryland transplanted pig hearts into two men who were out of other options, and both died within months.

Advertisement

Mass General’s pig kidney transplant last month raised new hopes. Kawai said Richard “Rick” Slayman experienced an early rejection scare but bounced back enough to go home earlier this month and still is faring well five weeks post-transplant. A recent biopsy showed no further problems.

A COMPLEX CASE AT NYU

Pisano is the first woman to receive a pig organ — and unlike with prior xenotransplant experiments, both her heart and kidneys had failed. She went into cardiac arrest and had to be resuscitated before the experimental surgeries. She’d gotten too weak to even play with her grandchildren. “I was miserable,” the Cookstown, New Jersey, woman said.

A failed heart made her ineligible for a traditional kidney transplant. But while on dialysis, she didn’t qualify for a heart pump, called a left ventricular assist device or LVAD, either.

“It’s like being in a maze and you can’t find a way out,” Montgomery explained — until the surgeons decided to pair a heart pump with a pig kidney.

TWO SURGERIES IN EIGHT DAYS

With emergency permission from the Food and Drug Administration, Montgomery chose an organ from a pig genetically engineered by United Therapeutics Corp. so its cells don’t produce a particular sugar that’s foreign to the human body and triggers immediate organ rejection.

Advertisement

Plus a tweak: The donor pig’s thymus gland, which trains the immune system, was attached to the donated kidney in hopes that it would help Pisano’s body tolerate the new organ.

Surgeons implanted the LVAD to power Pisano’s heart on April 4, and transplanted the pig kidney on April 12. There’s no way to predict her long-term outcome but she’s shown no sign of organ rejection so far, Montgomery said. And in adjusting the LVAD to work with her new kidney, Moazami said doctors already have learned lessons that could help future care of heart-and-kidney patients.

Special “compassionate use” experiments teach doctors a lot but it will take rigorous studies to prove if xenotransplants really work. What happens with Pisano and Mass General’s kidney recipient will undoubtedly influence FDA’s decision to allow such trials. United Therapeutics said it hopes to begin one next year.

Advertisement

Health

Brain aging may accelerate after cancer treatment, study suggests

Published

on

Brain aging may accelerate after cancer treatment, study suggests

NEWYou can now listen to Fox News articles!

Surviving cancer as a child or young adult may have a lasting impact on aging, new research suggests.

Researchers at the University of Rochester Medical Center looked at whether life-saving treatments, like chemotherapy and radiation, could speed up biological aging.

They also aimed to determine whether this age acceleration was linked to cognitive issues related to memory, focus and learning.

The team analyzed blood samples from a group of 1,400 long-term survivors treated at St. Jude Children’s Research Hospital, using epigenetic clocks — tools that estimate biological age by examining chemical tags on DNA.

Advertisement

Biological age is determined based on damage the cells accumulate over time, versus chronological age, which is measured by how long someone has been alive, according to scientists.

Biological age is determined based on the damage cells accumulate over time, according to scientists. (iStock)

“These well-established aging-related biomarkers have previously been associated with neurocognitive impairment and decline in older non-cancer populations, particularly in cognitive domains related to aging and dementia, such as memory, attention and executive function,” the study stated.

Most of the group consisted of acute lymphoblastic leukemia survivors, or Hodgkin lymphoma survivors. Participants were at least five years past their treatment, though some had survived for several decades.

They underwent neurocognitive testing to measure their attention span, memory and information processing speed.

Advertisement

CREATIVE HOBBIES KEEP THE BRAIN YOUNG, STUDY FINDS — HERE ARE THE BEST ONES TO PURSUE

Chemotherapy was found to have the greatest impact on aging acceleration. The study suggests the treatment can alter DNA structure and cause cellular damage.

CLICK HERE FOR MORE HEALTH STORIES

“It’s no surprise to find out that young people with cancer who have chemo early in life are affected in terms of long-term aging,” Dr. Marc Siegel, senior medical analyst for Fox News, told Fox News Digital.

Participants underwent neurocognitive testing to measure their attention span, memory and speed of information processing. (iStock)

Advertisement

Researchers also found that cellular aging was closely linked to cognitive performance, as survivors of a higher biological age had more difficulty with memory and attention.

“Chemo poisons and damages cellular function — hopefully the cancer cells more than normal cells, but there is a significant impact on normal cells as well,” said Siegel, who was not involved in the study.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“There is also something called ‘chemo brain,’ which causes at least temporary difficulty with memory, concentration, word finding and brain fog,” the doctor added.

The research team hopes to use these findings to focus on intervention efforts, specifically by determining when accelerated aging begins.

Advertisement

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Young cancer survivors have many more decades of life to live,” lead study author AnnaLynn Williams, PhD, said in a press release. “If these accelerated aging changes are occurring early on and setting them on a different trajectory, the goal is to intervene to not only increase their lifespan, but improve their quality of life.”

The team hopes this research will help in the development of early intervention tools that aim to prevent cognitive decline. (iStock)

There were some limitations to the study. The researchers could not adjust for chronic health conditions or education because they are directly impacted by treatment.

Additionally, the study only looked at the survivors at a single point of time, so it could not directly prove causation.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The study was published in the journal Nature Communications.

Fox News Digital reached out to the researchers for comment.

Related Article

4 anti-aging approaches revealed in 2025 that may help Americans live longer
Continue Reading

Health

GLP-1 Drugs Linked to Osteoporosis and Gout: Here’s How To Stay Safe

Published

on

GLP-1 Drugs Linked to Osteoporosis and Gout: Here’s How To Stay Safe


Advertisement




GLP-1 Drugs Linked To Increased Risk of Osteoporosis and Gout | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Ozempic-style drugs could slash complication risks after heart attacks, research suggests

Published

on

Ozempic-style drugs could slash complication risks after heart attacks, research suggests

NEWYou can now listen to Fox News articles!

A popular class of weight-loss drugs may prevent life-threatening cardiac complications by opening microscopic blood vessels that often remain blocked after a heart attack, according to a study published this week in Nature Communications.

The research, led by the University of Bristol and University College London, identified a biological brain-gut-heart signaling pathway. 

This discovery appears to explain how GLP-1 drugs — which mimic glucagon-like peptide-1, a hormone that helps regulate blood sugar and appetite — protect heart tissue from a condition known as “no-reflow.”

“In nearly half of all heart attack patients, tiny blood vessels within the heart muscle remain narrowed, even after the main artery is cleared during emergency medical treatment,” Dr. Svetlana Mastitskaya, the study’s lead author and a senior lecturer at Bristol Medical School, said in a press release.

Advertisement

“This results in a complication known as ‘no-reflow,’ where blood is unable to reach certain parts of the heart tissue.”

In nearly half of all heart attack patients, tiny capillaries (blood vessels) remain narrowed even after the main blocked artery is cleared. (iStock)

This lack of blood flow increases the risk of heart failure and death within a year. GLP-1 medications could prevent this, according to the researchers.

How it works

When the GLP-1 hormone is released in the gut or administered as a drug, it sends a signal to the brain, which then sends a signal to the heart that switches on special potassium channels in tiny cells called pericytes.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Advertisement

When these channels open, the pericytes relax, which allows the small blood vessels (capillaries) to widen and improve blood flow to the heart muscle, the researchers noted.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The new study used animal models and cellular imaging to track how GLP-1 interacts with heart tissue. When the researchers removed the potassium channels, the drugs no longer protected the heart — confirming they play a key role.

The findings suggest that existing GLP-1 medications, already used for type 2 diabetes and obesity, could be repurposed as emergency treatments. (iStock)

The findings suggest that existing GLP-1 medications, already used for type 2 diabetes and obesity, could be repurposed as emergency treatments during or immediately after a heart attack to reduce tissue damage.

Advertisement

CLICK HERE FOR MORE HEALTH STORIES

The researchers noted several limitations, including that the study relied on animal models.

Clinical trials are necessary to determine whether the brain-gut-heart pathway operates with the same timing and efficacy in humans.

While the study highlights the drug’s immediate benefits during a heart attack, it des not establish whether long-term use of these drugs provides a pre-existing level of protection. (iStock)

Additionally, while the study highlights the drug’s immediate benefits during a heart attack, it does not establish whether long-term use of the medication provides a pre-existing level of protection.

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The research was primarily funded by the British Heart Foundation.

Related Article

Eating oatmeal for two days has unexpected impact on heart health, study suggests
Advertisement
Continue Reading
Advertisement

Trending